Neon Therapeutics Inc (NASDAQ:NTGN) reached a new 52-week low during trading on Thursday . The company traded as low as $5.51 and last traded at $5.86, with a volume of 6649 shares trading hands. The stock had previously closed at $6.15.

A number of research firms have commented on NTGN. Zacks Investment Research upgraded Neon Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 price target on the stock in a research report on Friday, November 16th. LADENBURG THALM/SH SH began coverage on Neon Therapeutics in a research report on Monday, October 1st. They issued a “buy” rating and a $20.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, Neon Therapeutics presently has a consensus rating of “Buy” and an average target price of $18.08.

Neon Therapeutics (NASDAQ:NTGN) last released its quarterly earnings results on Monday, November 12th. The company reported ($0.67) EPS for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.12. As a group, sell-side analysts anticipate that Neon Therapeutics Inc will post -5.17 earnings per share for the current fiscal year.

Several institutional investors have recently made changes to their positions in the stock. Point72 Hong Kong Ltd bought a new stake in shares of Neon Therapeutics during the 2nd quarter valued at about $105,000. Northern Trust Corp bought a new stake in shares of Neon Therapeutics during the 2nd quarter valued at about $137,000. Highland Capital Management LP bought a new stake in shares of Neon Therapeutics during the 2nd quarter valued at about $137,000. Bain Capital Public Equity Management LLC bought a new stake in shares of Neon Therapeutics during the 2nd quarter valued at about $147,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Neon Therapeutics during the 3rd quarter valued at about $141,000. Institutional investors own 71.09% of the company’s stock.

WARNING: “Neon Therapeutics (NTGN) Reaches New 12-Month Low at $5.51” was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://www.dailypolitical.com/2018/12/08/neon-therapeutics-ntgn-reaches-new-12-month-low-at-5-51.html.

About Neon Therapeutics (NASDAQ:NTGN)

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

Featured Article: 52-Week High/Low Prices For Stock Selection

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.